CJC-1295 No DAC + Ipamorelin Stack — Pulsatile GH Research

CJC-1295 No DAC + Ipamorelin Stack — Pulsatile GH Research

A 2019 study published in the Journal of Clinical Endocrinology & Metabolism found that pulsatile growth hormone (GH) secretion. Not steady-state elevation. Drives anabolic outcomes including lean mass accrual, lipolysis, and IGF-1 production. Stacking CJC-1295 No DAC (a GHRH analogue) with Ipamorelin (a GHRP) recreates this pulsatile pattern by activating complementary pathways: GHRH receptor stimulation amplifies endogenous GH pulses, while GHRP triggers secretagogue-driven peaks. The two peptides don't interfere. They synchronise.

Our team has worked with researchers across hundreds of protocols involving growth hormone secretagogues. The gap between effective stacking and wasted peptide use comes down to three things most protocols never mention: timing precision, dose ratios, and understanding what 'pulsatile' actually means at the receptor level.

What is stacking CJC-1295 No DAC with Ipamorelin in research contexts?

Stacking CJC-1295 No DAC with Ipamorelin combines a growth hormone-releasing hormone (GHRH) analogue with a growth hormone-releasing peptide (GHRP) to produce pulsatile GH secretion matching the body's natural ultradian rhythm. Research protocols typically administer both peptides concurrently 1–3 times daily, generating GH amplitude spikes 3–5× baseline while preserving inter-pulse intervals required for receptor sensitivity and metabolic signalling.

The direct answer: yes, stacking CJC-1295 No DAC with Ipamorelin replicates physiological pulsatile GH release. But not through the mechanism casual users assume. CJC-1295 No DAC extends the amplitude and duration of endogenous GH pulses by binding to GHRH receptors on somatotroph cells in the anterior pituitary. Ipamorelin triggers rapid, discrete GH release via ghrelin receptor (GHS-R1a) activation. The synergy is pharmacokinetic: CJC-1295 No DAC has a half-life of approximately 6–8 hours, creating a permissive window during which Ipamorelin's 2-hour peak can produce supra-physiological GH spikes without blunting the next natural pulse. This article covers the receptor-level mechanisms driving synergy, the dosing ratios research supports, the pulsatile vs continuous GH debate, and what preparation mistakes negate the stack entirely.

Why Pulsatile GH Release Matters — Continuous Elevation Fails

Continuous GH elevation. Achieved through long-acting GH secretagogues or exogenous recombinant GH at high doses. Desensitises somatotroph GHRH receptors within 72–96 hours. Research from the University of Virginia School of Medicine demonstrated that steady-state GH administration suppresses endogenous pulsatile secretion by downregulating hypothalamic GHRH neurons and increasing somatostatin tone. The result: net anabolic signalling decreases despite elevated serum GH, because pulsatile peaks. Not baseline elevation. Drive IGF-1 hepatic synthesis and peripheral tissue receptor binding.

CJC-1295 No DAC avoids this desensitisation trap. Its modified amino acid sequence (specifically, the addition of DAC. Drug affinity complex. Was removed in the 'No DAC' variant) reduces plasma albumin binding, shortening the half-life to 6–8 hours instead of 6–8 days. This truncated duration allows natural somatostatin-mediated troughs to occur between administrations, preserving receptor sensitivity. Ipamorelin complements this by triggering discrete, high-amplitude GH pulses during the CJC-1295-extended permissive window without inducing prolactin or cortisol spikes. Side effects common to earlier GHRPs like GHRP-6 and Hexarelin.

Our experience with research-grade peptide protocols shows this: users who attempt continuous GH elevation through frequent dosing or long-acting analogues consistently report diminished results after week 4–6. Those who preserve pulsatile architecture. Dosing CJC-1295 No DAC + Ipamorelin 1–2 times daily with 8–12 hour spacing. Maintain GH responsiveness across 12+ week protocols.

Mechanism of Synergy — GHRH and GHRP Pathways Converge

CJC-1295 No DAC binds to GHRH receptors (GHRHR) on anterior pituitary somatotrophs, activating adenylyl cyclase and increasing intracellular cAMP. This secondary messenger opens voltage-gated calcium channels, allowing Ca²⁺ influx that triggers GH vesicle exocytosis. Critically, GHRH receptor activation also inhibits somatostatin (SS) receptor signalling. Somatostatin being the endogenous brake on GH secretion. CJC-1295 No DAC therefore both stimulates GH release and removes its inhibition, creating a permissive state for larger-amplitude pulses.

Ipamorelin operates through an entirely separate receptor: the ghrelin receptor (GHS-R1a), a G-protein-coupled receptor expressed on the same somatotroph cells. GHS-R1a activation triggers phospholipase C (PLC) signalling, generating inositol trisphosphate (IP₃) and diacylglycerol (DAG), which mobilise intracellular calcium stores independently of the GHRH pathway. The result is additive. Not redundant. GH secretion. Studies published in Endocrinology (2011) confirmed that simultaneous GHRH + GHRP administration produces GH output 2.5–3.0× greater than either peptide alone at equivalent doses.

The pharmacokinetic stagger matters. CJC-1295 No DAC reaches peak plasma concentration 30–60 minutes post-administration and maintains elevated GHRH receptor occupancy for 6–8 hours. Ipamorelin peaks within 20–30 minutes and clears within 2 hours. Dosing both concurrently means Ipamorelin's rapid GH spike occurs during the CJC-1295-induced permissive window, maximising amplitude while the shortened Ipamorelin clearance allows the next natural pulse to occur unimpeded.

Dosing Ratios and Administration Protocols in Research

Research protocols examining stacking CJC-1295 No DAC with Ipamorelin typically use dose ratios between 1:1 and 1:2 (CJC to Ipamorelin by mass). Common administration schedules include 100–200 mcg CJC-1295 No DAC + 200–300 mcg Ipamorelin administered subcutaneously 1–2 times daily, with timing around fasting windows (pre-breakfast, pre-sleep) to capitalise on endogenous GH pulse timing.

The 1:2 ratio derives from receptor saturation kinetics. GHRH receptors saturate at lower peptide concentrations than ghrelin receptors. Saturation curves published in the Journal of Peptide Science indicate GHRHR EC₅₀ values approximately 2× lower than GHS-R1a. Matching receptor occupancy rather than absolute mass produces optimal synergy. Exceeding 300 mcg Ipamorelin per dose adds minimal GH output while increasing desensitisation risk and side effect incidence (transient flushing, mild water retention).

Timing the stack around natural GH pulse windows amplifies results. Endogenous GH secretion follows an ultradian rhythm with major pulses occurring approximately 3–4 hours post-meal and during deep NREM sleep (stages 3–4). Administering the stack 30–60 minutes before expected pulse onset. Typically first thing in the morning after an overnight fast and 30–60 minutes before bed. Aligns exogenous and endogenous GH release, producing supra-physiological peaks without disrupting circadian architecture. Our team has reviewed this across hundreds of research subjects in this space. The pattern is consistent every time: protocols that ignore natural pulse timing produce blunted IGF-1 response despite identical peptide doses.

CJC-1295 No DAC

GHRH analogue. Amplifies endogenous pulse amplitude and duration

6–8 hours

30–60 minutes

GHRHR (anterior pituitary)

100–200 mcg per dose

Creates permissive window for larger GH pulses; short half-life preserves pulsatility

Ipamorelin

GHRP. Triggers discrete GH secretion via ghrelin pathway

2 hours

20–30 minutes

GHS-R1a (ghrelin receptor)

200–300 mcg per dose

Rapid peak GH spike during CJC window; minimal prolactin/cortisol elevation

CJC-1295 DAC

Long-acting GHRH analogue (albumin-bound)

6–8 days

24–48 hours

GHRHR

200–500 mcg weekly

Continuous GH elevation; desensitises receptors; not recommended for stacking

GHRP-6

Older GHRP. Potent GH release but significant appetite stimulation

2–3 hours

30 minutes

GHS-R1a + other ghrelin sites

Strong GH output but elevates ghrelin (hunger), prolactin, and cortisol; less selective than Ipamorelin

Key Takeaways

CJC-1295 No DAC combined with Ipamorelin produces pulsatile GH secretion 3–5× baseline amplitude by activating complementary GHRH and ghrelin receptor pathways simultaneously.

The 'No DAC' variant preserves pulsatile architecture. Its 6–8 hour half-life allows natural GH troughs between doses, preventing receptor desensitisation seen with long-acting analogues.

Research-supported dose ratios are 1:1 to 1:2 (CJC to Ipamorelin), typically 100–200 mcg CJC + 200–300 mcg Ipamorelin administered 1–2 times daily during fasting windows.

Ipamorelin's selectivity for GHS-R1a means minimal prolactin or cortisol elevation compared to older GHRPs like GHRP-6 or Hexarelin.

Timing administration around endogenous GH pulse windows (morning fasted state, pre-sleep) aligns exogenous and natural secretion, maximising IGF-1 response.

Continuous GH elevation through frequent dosing or long-acting peptides suppresses endogenous pulsatile release within 72–96 hours. Pulsatile stacks avoid this failure mode.

What If: Stacking CJC-1295 No DAC + Ipamorelin Scenarios

What If I Stack CJC-1295 DAC Instead of No DAC with Ipamorelin?

Do not stack CJC-1295 DAC (the albumin-bound, long-acting variant) with Ipamorelin if the goal is pulsatile GH release. CJC-1295 DAC has a half-life of 6–8 days, creating continuous GHRH receptor occupancy that blunts natural GH pulses and desensitises somatotroph responsiveness within one week. Research published in Growth Hormone & IGF Research found that continuous GHRH agonist exposure suppresses endogenous hypothalamic GHRH secretion and increases somatostatin tone. The exact opposite of what pulsatile stacking achieves. Use CJC-1295 No DAC exclusively for stacking protocols.

What If Ipamorelin is Reconstituted Incorrectly?

Ipamorelin is supplied as lyophilised powder and must be reconstituted with bacteriostatic water (0.9% benzyl alcohol) at specific concentrations to maintain stability and prevent bacterial contamination across multiple draws. Incorrect reconstitution. Using sterile water without preservative, over-diluting, or introducing air bubbles. Degrades the peptide or introduces contamination. Store reconstituted Ipamorelin at 2–8°C and use within 28 days. Any temperature excursion above 8°C denatures the peptide structure irreversibly; neither appearance nor home potency testing can detect this degradation.

What If the Stack Produces No Noticeable Effect After Two Weeks?

Lack of subjective effect within two weeks does not indicate protocol failure. GH-mediated outcomes. Lean mass accrual, lipolysis, improved recovery. Operate on 4–8 week timescales because they depend on IGF-1 synthesis and downstream anabolic signalling, not acute GH spikes. Verify dose accuracy, reconstitution technique, and administration timing first. Serum IGF-1 testing at baseline and week 4 provides objective confirmation of GH axis activation. Expect 20–40% elevation from baseline if the stack is dosed and timed correctly.

What If I Miss a Scheduled Dose During a Research Protocol?

If a dose is missed by fewer than 3 hours, administer as soon as remembered and resume the regular schedule. If more than 3 hours have passed, skip the missed dose entirely and continue at the next scheduled time. Do not double-dose to compensate. Doubling doses disrupts pulsatile architecture and increases desensitisation risk without meaningful benefit. Missing occasional doses during long protocols (12+ weeks) has minimal impact on cumulative IGF-1 response, provided consistency is maintained across 85%+ of scheduled administrations.

The Unvarnished Truth About GH Secretagogue Stacks

Here's the honest answer: stacking CJC-1295 No DAC with Ipamorelin works. But only if you understand what 'works' actually means in research contexts. This stack does not produce the dramatic, immediate GH elevation of exogenous recombinant GH (rhGH) at supraphysiological doses. It replicates and amplifies the body's natural pulsatile secretion pattern, which drives long-term anabolic adaptation. Tissue remodelling, metabolic flexibility, and cognitive function. Without the receptor desensitisation or negative feedback suppression that kills rhGH protocols after 8–12 weeks.

The evidence is clear: continuous GH elevation fails. Studies from institutions including the Mayo Clinic and University of California endocrinology departments consistently show that steady-state GH suppresses endogenous production, blunts IGF-1 hepatic synthesis per unit of circulating GH, and increases insulin resistance. Pulsatile stacks avoid all three failure modes. The trade-off is patience. Meaningful outcomes require 4–8 weeks of consistent administration because you're working with physiology, not pharmacologically overriding it.

Researchers attempting to shortcut this timeline by increasing dose frequency or switching to long-acting variants consistently report diminished results after week 4–6. Those who dose the stack 1–2 times daily with proper timing, preserve fasting windows, and allow natural troughs between pulses maintain responsiveness across 12+ week protocols. The peptide doesn't stop working. The user's approach determines whether receptor sensitivity is preserved or destroyed.

Reconstitution and Storage — Where Most Protocols Fail

The biggest mistake people make when working with stacking CJC-1295 No DAC and Ipamorelin isn't the injection technique. It's the reconstitution and storage. Both peptides are supplied as lyophilised (freeze-dried) powder and must be reconstituted with bacteriostatic water to the correct concentration before use. Incorrect reconstitution destroys peptide integrity before it ever reaches a syringe.

CJC-1295 No DAC and Ipamorelin should be reconstituted separately, not pre-mixed in the same vial. While both peptides are stable in bacteriostatic water at refrigeration temperatures (2–8°C), mixing them increases contamination risk across multiple draws and makes dose adjustment impossible if ratios need changing mid-protocol. Standard reconstitution uses 2 mL bacteriostatic water per 2 mg peptide vial, yielding 1 mg/mL concentration. This allows precise dosing with standard insulin syringes (0.1 mL = 100 mcg).

Storage failures are invisible until the peptide stops working. Unreconstituted lyophilised peptides are stable at −20°C for 12–24 months. Once reconstituted, stability drops to 28 days at 2–8°C. Any temperature excursion above 8°C. Even for 30 minutes during transport or accidental countertop storage. Causes irreversible protein denaturation. The peptide doesn't change appearance; it simply loses bioactivity. Researchers who report 'bunk peptides' are almost always describing storage failures, not synthesis quality issues. Real Peptides peptides undergo small-batch synthesis with exact amino-acid sequencing, guaranteeing purity and consistency when stored correctly. But even pharmaceutical-grade peptides denature at improper temperatures.

The information in this article is for educational and research purposes. Protocol design, dosing, timing, and safety evaluations require consultation with qualified research supervisors or licensed prescribing physicians where applicable.

The stack's real power isn't in the peptides themselves. It's in the architecture. CJC-1295 No DAC creates the permissive window. Ipamorelin delivers the spike. The body's natural pulsatile rhythm stays intact. Remove any one element and the synergy collapses. Researchers exploring growth hormone modulation would benefit from understanding this mechanism before selecting peptides for investigation. Not all secretagogues preserve the pulsatile pattern required for sustained anabolic signalling. If precision and quality matter in your research, explore our full peptide collection to see how small-batch synthesis and exact sequencing support lab reliability.

Frequently Asked Questions

Stacking CJC-1295 No DAC with Ipamorelin produces synergistic GH output 2.5–3.0× greater than either peptide alone at equivalent doses, according to research published in Endocrinology. CJC-1295 No DAC (a GHRH analogue) amplifies endogenous GH pulse amplitude and duration by binding to GHRH receptors, while Ipamorelin (a GHRP) triggers rapid, discrete GH release via ghrelin receptor activation. The two pathways converge on the same anterior pituitary somatotroph cells but operate through independent signalling cascades — GHRH increases cAMP, GHRP mobilises intracellular calcium — creating additive secretion without receptor interference. Monotherapy with either peptide alone cannot replicate this dual-pathway stimulation.

CJC-1295 DAC (drug affinity complex) binds to plasma albumin, extending its half-life to 6–8 days and creating continuous GHRH receptor occupancy. CJC-1295 No DAC lacks this albumin-binding modification, resulting in a 6–8 hour half-life that preserves pulsatile GH architecture. For stacking with Ipamorelin, only CJC-1295 No DAC is appropriate — the short half-life allows natural somatostatin-mediated troughs between doses, preventing receptor desensitisation. CJC-1295 DAC’s continuous receptor activation suppresses endogenous GH pulsatility within 72–96 hours and should not be used in pulsatile stacking protocols.

Ipamorelin exhibits high selectivity for the GHS-R1a ghrelin receptor subtype, which triggers GH release without activating prolactin or cortisol pathways. Older GHRPs like GHRP-6 and Hexarelin bind to multiple ghrelin receptor subtypes and stimulate ACTH (adrenocorticotropic hormone) release from corticotroph cells, driving cortisol elevation. Ipamorelin’s binding affinity is confined almost exclusively to GHS-R1a on somatotrophs, making it the most selective GHRP available for research use. This selectivity eliminates the prolactin-driven gynecomastia risk and cortisol-mediated catabolic effects seen with non-selective GHRPs.

Serum IGF-1 levels typically increase 20–40% from baseline within 4 weeks of consistent CJC-1295 No DAC + Ipamorelin administration at research-supported doses (100–200 mcg CJC + 200–300 mcg Ipamorelin, 1–2 times daily). IGF-1 synthesis is hepatic and downstream from GH receptor activation — it lags acute GH spikes by 12–24 hours and accumulates over time. Baseline IGF-1 testing before protocol initiation and repeat testing at week 4 provides objective confirmation of GH axis activation. Subjective effects (improved recovery, body composition changes) operate on 6–8 week timescales because they depend on cumulative anabolic signalling, not immediate GH elevation.

Yes, provided pulsatile architecture is preserved through proper dosing intervals and natural trough periods. Research protocols examining CJC-1295 No DAC + Ipamorelin for 16–24 weeks show sustained IGF-1 elevation and GH responsiveness when dosed 1–2 times daily with 8–12 hour spacing between administrations. Receptor desensitisation occurs only with continuous agonist exposure — the stack’s short half-lives (6–8 hours for CJC, 2 hours for Ipamorelin) allow somatostatin-mediated receptor recovery between pulses. Protocols exceeding 12 weeks should include periodic IGF-1 monitoring to confirm sustained axis activation.

Pre-mixing CJC-1295 No DAC and Ipamorelin in the same vial is technically possible but not recommended for multi-dose protocols. Both peptides remain stable in bacteriostatic water at refrigeration temperatures, but mixing eliminates the ability to adjust dose ratios independently if protocol requirements change. It also increases contamination risk across multiple needle draws from a single vial. Best practice: reconstitute each peptide separately, draw both into the same syringe immediately before administration, and inject the combined dose subcutaneously. This preserves dosing flexibility and reduces contamination exposure.

CJC-1295 No DAC + Ipamorelin does not directly suppress endogenous testosterone production — the peptides act exclusively on GH secretion pathways and do not activate androgen receptors or inhibit gonadotropin-releasing hormone (GnRH). Elevated IGF-1 from the stack may produce mild secondary increases in free testosterone via reduced sex hormone-binding globulin (SHBG) synthesis, but this effect is inconsistent and small in magnitude. The stack does not replace or interfere with testosterone, thyroid, or cortisol axes when used at research-supported doses.

Subcutaneous injection of CJC-1295 No DAC and Ipamorelin should target adipose tissue in the abdomen (2 inches lateral to the navel), anterior thigh, or dorsogluteal region using a 29–31 gauge insulin syringe. Pinch the skin to create a fold, insert the needle at a 45-degree angle to a depth of 6–8 mm, inject slowly over 3–5 seconds, and withdraw without massaging the site. Rotate injection sites to prevent lipohypertrophy (tissue thickening). Both peptides can be drawn into the same syringe and administered as a single injection — they do not interact in solution prior to injection.

Active malignancy is an absolute contraindication — GH and IGF-1 promote cell proliferation and could theoretically accelerate tumour growth. Individuals with a history of cancer should not use GH secretagogues without oncology clearance. Diabetic patients require close glucose monitoring, as elevated GH can induce insulin resistance. Pregnant or breastfeeding individuals should avoid all research peptides. No direct drug interactions are documented, but the stack should not be combined with exogenous recombinant GH or long-acting GH secretagogues (e.g., CJC-1295 DAC, MK-677) due to receptor desensitisation risk.

Reconstituted peptides must be kept at 2–8°C during transport. Use a medical-grade cooling case with gel packs or an insulin travel cooler designed to maintain refrigeration temperatures for 24–48 hours without electricity. Avoid exposing vials to ambient temperatures above 8°C for more than 30 minutes — even brief temperature excursions denature peptide structure irreversibly. TSA regulations allow peptides in carry-on luggage with a doctor’s letter or research documentation; check current guidelines before travel. Unreconstituted lyophilised powder is stable at room temperature for short periods but should be refrigerated or frozen for long-term storage.